A new approach examines how individual cells respond to drugs, aiming to identify risks earlier in development.
Updated
April 15, 2026 6:01 PM
Close up of a capsule blister pack. PHOTO: UNSPLASH
DeepCyte, a startup in the drug development space, is focusing on a long-standing problem: why drugs that appear safe in early testing still fail in clinical trials or are withdrawn later due to toxicity. DeepCyte has launched with US$1.5 million in seed funding to build tools that detect and explain the harmful effects of drugs at much earlier stages.
The startup’s approach focuses on how individual cells respond to a drug. Instead of analysing cells in bulk, it studies them one by one. This helps capture differences in how cells react, which are often missed in traditional testing methods.
Drug toxicity remains one of the main reasons for failure in drug development. Methods such as animal testing and bulk cell analysis do not always reflect how human cells behave. This gap has pushed the industry to look for more reliable and human-relevant ways to test drug safety.
DeepCyte combines cell-level data with artificial intelligence. Its platform, MetaCore, studies what is happening inside individual cells by capturing detailed molecular information. This data is used to build large datasets that can train AI models.
Additionally, the company has developed an AI system called DeeImmuno. It is designed to predict whether a drug could be toxic and identify the biological reasons behind it. In internal testing on 100 drugs, the system identified different types of toxicity and their underlying mechanisms with a reported accuracy of 94 percent.
The focus on explaining why a drug is toxic, not just whether it is, reflects a broader shift in the industry. Regulators such as the U.S. Food and Drug Administration and the European Medicines Agency have been encouraging methods that rely more on human cell data and clearer biological evidence. The seed funding will be used to develop and scale these tools. The company aims to help drug developers make earlier decisions, which could reduce costly failures in later stages. Whether tools like this become widely used will depend on how they perform in real-world settings. For now, DeepCyte’s approach highlights a growing effort to make drug testing more precise by focusing on how drugs affect cells at the most detailed level.
Keep Reading
From pre-orders to market entry, Rokid’s Taiwan campaign reflects how AI hardware is being introduced to consumers today.
Updated
January 8, 2026 6:30 PM
Rokid Glasses, a pair of AR glasses from Rokid. PHOTO: ROKID
Rokid has reached a significant crowdfunding milestone in Taiwan. Its Rokid Glasses campaign surpassed NT$62 million in pre-order funding on zeczec, Taiwan’s creative-oriented crowdfunding platform. The campaign ranked No. 1 across all categories on the platform in 2025 and entered the Top 10 funded campaigns in zeczec’s history, setting new records for AI and XR-related projects.
The campaign launched on October 28 and became one of the platform’s most prominent technology initiatives of the year. According to the company, the outcome followed growing visibility for Rokid Glasses after product showcases in New York, Berlin, Singapore and Paris, positioning the Taiwan campaign within a broader international rollout.
The crowdfunding achievement coincided with Rokid’s official market entry in Taiwan. On December 10, the company debuted Rokid Glasses locally, introducing the product to media, partners and early users in the region. The Taiwan launch mirrored earlier international events and connected the online crowdfunding campaign with a physical market presence.
Rokid Glasses combine augmented reality displays with built-in AI functions, including real-time multilingual translation, live transcription, navigation, object recognition and voice assistance. These capabilities were central to how the product was presented during both the crowdfunding campaign and the Taiwan launch, without framing the project as a traditional consumer electronics release.
The Taiwan campaign builds on Rokid’s prior crowdfunding history. The company previously raised more than US$4 million on Kickstarter, where Rokid Glasses became the highest-funded XR wearable project on the platform. The zeczec campaign extends that track record into one of Asia’s most established consumer electronics markets.
“Taiwan has one of the world's most mature and discerning consumer electronics markets”, said Said Justo Chang, Head of Global Channels at Rokid. “Reaching the top of Taiwan's crowdfunding platform is a great commercial achievement. We are excited to finally introduce Rokid Glasses to Taiwan”.
More broadly, the campaign highlights how crowdfunding platforms continue to function as launch and distribution channels for emerging AI and XR hardware. In Rokid’s case, product rollout, market entry and public participation converged within a single campaign, marking a notable moment for AI-enabled wearables in Taiwan’s technology landscape.